Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies.
Location: China, Zhejiang, Hangzhou City
Employees: 11-50
Total raised: $25.5M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Alta Partn... | altapartne... |
| 08.11.2023 | ARCH Ventu... | archventur... |
| 09.02.2022 | Matrix Par... | matrixpart... |
| - | Northern L... | nlvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.09.2019 | Series A | $25.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.09.2023 | Deals in brief: AnyMind Group acquires Indonesia-based DDI, GGV Capital splits into two businesses, eight China deals, and more | AnyMind Group acquires Digital Distribusi Indonesia The Singapore-founded brand enablement company has acquired Digital Distribusi Indonesia (DDI), an Indonesia-based e-commerce enabler and distributor. The acquisition will enable AnyMind G... |
| 29.03.2021 | China’s Qihan Biotech nets $67m funding from LAV, Sequoia, others | Gene technology-focused Qihan Biotech on Monday said it has bagged as much as $67 million in its Series A++ round from a slew of investors. Lilly Asia Ventures and Matrix Partners China were the new investors in the round while return backe... |
| 29.03.2021 | China’s Qihan Biotech nets $67m funding from LAV, Sequoia, others | Premium Gene technology-focused Qihan Biotech on Monday said it has bagged as much as $67 million in its Series A++ round from a slew of investors. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subsc... |
| 29.03.2021 | Qihan Biotech Raises Additional USD 67 Million in Series A++ Financing | Qihan Biotechnology Co. Ltd (“Qihan” or “the Company”), a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ fin... |
| 23.09.2019 | China’s gene-editing startup Qihan Biotech raises $25.5m in Series A+ round | Premium Chinese gene-editing technology developer Qihan Biotech announced on Monday that it has secured $25.5 million in a Series A+ funding round, bringing life-saving organ transplantation solutions to serve the largely untapped market in... |